Actelion & Nippon Shinyaku vs. Cipla: Selexipag Patent Victory Secured by Consent Judgment
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Actelion Pharmaceuticals US, Inc. et al. v. Cipla Limited et al. |
| Case Number | 1:22-cv-01450 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Nov 2022 – Aug 2024 1 year 9 months |
| Outcome | Plaintiff Win — Permanent Injunction |
| Patents at Issue | |
| Accused Products | Selexipag for injection 1.8 mg/vial (generic Uptravi® IV) |
Case Overview
The Parties
⚖️ Plaintiff
Subsidiaries of Johnson & Johnson’s Janssen division and Nippon Shinyaku Co., Ltd., holding IP for Uptravi®, an FDA-approved therapy for pulmonary arterial hypertension (PAH).
🛡️ Defendant
Prominent generics manufacturers with an extensive ANDA pipeline, specializing in various therapeutic areas including pulmonary arterial hypertension.
The Patents at Issue
This case centered on two foundational selexipag patents protecting specific polymorphic crystal form claims — a sophisticated and commercially critical layer of pharmaceutical IP strategy. Such patents are frequently challenged on grounds of obviousness (§103) or lack of written description (§112).
- • U.S. Patent No. 8,791,122 — Covers the Form-I crystal of selexipag and methods for its production.
- • U.S. Patent No. 9,284,280 — Covers the use of the same Form-I crystalline compound, extending IP protection.
Developing a generic pharmaceutical?
Ensure your ANDA product doesn’t infringe existing crystalline form or method-of-use patents.
The Verdict & Legal Analysis
Outcome
The case resolved via Consent Judgment and Order of Permanent Injunction. Cipla Limited and Cipla USA, Inc. acknowledged the validity and enforceability of U.S. Patent Nos. 8,791,122 and 9,284,280 and agreed to a permanent injunction, blocking their generic selexipag injection product until patent expiration. No monetary damages were publicly disclosed.
Verdict Cause Analysis
The action was a classic Hatch-Waxman paragraph IV ANDA infringement suit, triggered by Cipla’s ANDA No. 216607. The crystalline form patents, protecting the Form-I polymorph of selexipag, represent a sophisticated layer of pharmaceutical patent protection. Cipla’s stipulation to validity indicates a strategic decision to resolve the litigation rather than risk adverse rulings at trial.
Legal Significance
The explicit acknowledgment of patent validity and enforceability in the consent judgment, though limited to this action, sets a precedent. It strengthens Actelion and Nippon Shinyaku’s position against other ANDA filers for Uptravi® IV, including remaining defendants Alembic and Lupin. This outcome reinforces that crystalline form patents are powerful tools in pharmaceutical lifecycle management strategies.
Strategic Takeaways
For Patent Holders: Layering composition-of-matter patents with use and method claims creates multi-dimensional enforcement leverage. Seeking permanent injunctions via consent judgment preserves IP protection without the precedential risk of adverse claim construction rulings at trial.
For Accused Infringers (ANDA Filers): A thorough evaluation of invalidity defenses, especially against polymorphic form claims, is critical before committing to Paragraph IV certification litigation. Consent judgments with dismissal without prejudice can preserve future optionality if the patent landscape changes.
For R&D and Regulatory Teams: Design-around strategies for crystalline form patents are scientifically and commercially demanding. Freedom-to-operate (FTO) analyses must meticulously account for base compound patents, and downstream form, use, and manufacturing process patents.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical product development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all related patents in this therapeutic space
- See which companies are most active in PAH drug patents
- Understand crystalline form patent trends
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical compound or formulation.
- Input your compound structure or technical features
- AI identifies potentially blocking polymorphic patents
- Get actionable risk assessment report
High Risk Area
Crystalline form patents for API
2 Patents in Focus
US8791122 & US9284280
Design-Around Options
Complex, but feasible with specific polymorphs
✅ Key Takeaways
Consent judgments with validity stipulations are powerful enforcement outcomes in ANDA litigation, avoiding trial exposure.
Search related case law →Crystalline form patents continue to withstand challenge when properly prosecuted with robust written description and non-obviousness support.
Explore precedents →Delaware remains the premier jurisdiction for pharmaceutical patent enforcement due to its experienced bench and predictable procedures.
Analyze court trends →Frequently Asked Questions
The case involved U.S. Patent Nos. 8,791,122 and 9,284,280, both covering the Form-I crystalline structure of selexipag and its applications, protecting the active ingredient in Uptravi® IV.
Cipla stipulated to the validity and enforceability of both patents and agreed to a permanent injunction barring commercialization of its ANDA product (selexipag for injection 1.8 mg/vial) until patent expiration, resolving the action without a full merits trial.
The validity stipulation and permanent injunction strengthen Actelion and Nippon Shinyaku’s enforcement posture against remaining ANDA filers, signaling robust patent coverage that generic challengers must overcome through alternative legal strategies or post-grant proceedings.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER Case Lookup – 1:22-cv-01450
- USPTO Patent Full-Text Database – US 8,791,122
- USPTO Patent Full-Text Database – US 9,284,280
- FDA Orange Book – Hatch-Waxman Litigation Guide
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.